Cargando…
Phase I study evaluating the safety, tolerability and pharmacokinetics of a novel oral dissolvable film containing dexamethasone versus Fortecortin dexamethasone tablets
Introduction: Systemic corticosteroids are anti-inflammatory agents with dexamethasone among the most potent in the class. Within (respiratory) allergy, systemic corticosteroids are usually applied in medical emergencies. In these situations, patients may experience physical or logistic problems tak...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553100/ https://www.ncbi.nlm.nih.gov/pubmed/28815005 http://dx.doi.org/10.1080/20018525.2017.1353395 |
_version_ | 1783256580839440384 |
---|---|
author | Diamant, Zuzana Samuelsson Palmgren, Gabriella Westrin, Bengt Bjermer, Leif |
author_facet | Diamant, Zuzana Samuelsson Palmgren, Gabriella Westrin, Bengt Bjermer, Leif |
author_sort | Diamant, Zuzana |
collection | PubMed |
description | Introduction: Systemic corticosteroids are anti-inflammatory agents with dexamethasone among the most potent in the class. Within (respiratory) allergy, systemic corticosteroids are usually applied in medical emergencies. In these situations, patients may experience physical or logistic problems taking tablets. To fulfil a practical unmet need for outpatients, Dexa ODF, an oral dissolvable film containing dexamethasone, was developed. Objectives: We compared the safety, tolerability and pharmacokinetics (PK) of Dexa ODF with Fortecortin tablets in healthy subjects. Methods: Thirty subjects participated in this open label, two-way, cross-over study, consisting of two treatment visits separated by 5–10 days. On both treatment visits, subjects randomly received one single dose of Dexa ODF (one strip; 8 mg dexamethasone) or one single dose of Fortecortin (two 4 mg tablets). Safety evaluations and blood sampling for PK were conducted until 48 h post-dose and bioequivalence analysis was performed on AUC(0-t), AUC(0-∞) and Cmax. Results: All subjects were dosed. Forty-five adverse events (AEs) were reported by 17 subjects and approximately 50% were deemed ‘possibly treatment related’ (14 on Dexa ODF; 12 on Fortecortin) with no significant difference between treatments. For all three bioequivalence parameters the 90% CIs were within the acceptance limits of bioequivalence (0.8;1.25). Conclusion: We demonstrated good tolerability and bioequivalence of Dexa ODF (8 mg dexamethasone) compared to Fortecortin tablets (2 × 4 mg dexamethasone). Dexa ODF is currently under development as an innovative treatment for use within respiratory and allergic conditions, including emergencies. |
format | Online Article Text |
id | pubmed-5553100 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-55531002017-08-16 Phase I study evaluating the safety, tolerability and pharmacokinetics of a novel oral dissolvable film containing dexamethasone versus Fortecortin dexamethasone tablets Diamant, Zuzana Samuelsson Palmgren, Gabriella Westrin, Bengt Bjermer, Leif Eur Clin Respir J Original Article Introduction: Systemic corticosteroids are anti-inflammatory agents with dexamethasone among the most potent in the class. Within (respiratory) allergy, systemic corticosteroids are usually applied in medical emergencies. In these situations, patients may experience physical or logistic problems taking tablets. To fulfil a practical unmet need for outpatients, Dexa ODF, an oral dissolvable film containing dexamethasone, was developed. Objectives: We compared the safety, tolerability and pharmacokinetics (PK) of Dexa ODF with Fortecortin tablets in healthy subjects. Methods: Thirty subjects participated in this open label, two-way, cross-over study, consisting of two treatment visits separated by 5–10 days. On both treatment visits, subjects randomly received one single dose of Dexa ODF (one strip; 8 mg dexamethasone) or one single dose of Fortecortin (two 4 mg tablets). Safety evaluations and blood sampling for PK were conducted until 48 h post-dose and bioequivalence analysis was performed on AUC(0-t), AUC(0-∞) and Cmax. Results: All subjects were dosed. Forty-five adverse events (AEs) were reported by 17 subjects and approximately 50% were deemed ‘possibly treatment related’ (14 on Dexa ODF; 12 on Fortecortin) with no significant difference between treatments. For all three bioequivalence parameters the 90% CIs were within the acceptance limits of bioequivalence (0.8;1.25). Conclusion: We demonstrated good tolerability and bioequivalence of Dexa ODF (8 mg dexamethasone) compared to Fortecortin tablets (2 × 4 mg dexamethasone). Dexa ODF is currently under development as an innovative treatment for use within respiratory and allergic conditions, including emergencies. Taylor & Francis 2017-08-03 /pmc/articles/PMC5553100/ /pubmed/28815005 http://dx.doi.org/10.1080/20018525.2017.1353395 Text en © 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Diamant, Zuzana Samuelsson Palmgren, Gabriella Westrin, Bengt Bjermer, Leif Phase I study evaluating the safety, tolerability and pharmacokinetics of a novel oral dissolvable film containing dexamethasone versus Fortecortin dexamethasone tablets |
title | Phase I study evaluating the safety, tolerability and pharmacokinetics of a novel oral dissolvable film containing dexamethasone versus Fortecortin dexamethasone tablets |
title_full | Phase I study evaluating the safety, tolerability and pharmacokinetics of a novel oral dissolvable film containing dexamethasone versus Fortecortin dexamethasone tablets |
title_fullStr | Phase I study evaluating the safety, tolerability and pharmacokinetics of a novel oral dissolvable film containing dexamethasone versus Fortecortin dexamethasone tablets |
title_full_unstemmed | Phase I study evaluating the safety, tolerability and pharmacokinetics of a novel oral dissolvable film containing dexamethasone versus Fortecortin dexamethasone tablets |
title_short | Phase I study evaluating the safety, tolerability and pharmacokinetics of a novel oral dissolvable film containing dexamethasone versus Fortecortin dexamethasone tablets |
title_sort | phase i study evaluating the safety, tolerability and pharmacokinetics of a novel oral dissolvable film containing dexamethasone versus fortecortin dexamethasone tablets |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553100/ https://www.ncbi.nlm.nih.gov/pubmed/28815005 http://dx.doi.org/10.1080/20018525.2017.1353395 |
work_keys_str_mv | AT diamantzuzana phaseistudyevaluatingthesafetytolerabilityandpharmacokineticsofanoveloraldissolvablefilmcontainingdexamethasoneversusfortecortindexamethasonetablets AT samuelssonpalmgrengabriella phaseistudyevaluatingthesafetytolerabilityandpharmacokineticsofanoveloraldissolvablefilmcontainingdexamethasoneversusfortecortindexamethasonetablets AT westrinbengt phaseistudyevaluatingthesafetytolerabilityandpharmacokineticsofanoveloraldissolvablefilmcontainingdexamethasoneversusfortecortindexamethasonetablets AT bjermerleif phaseistudyevaluatingthesafetytolerabilityandpharmacokineticsofanoveloraldissolvablefilmcontainingdexamethasoneversusfortecortindexamethasonetablets |